Experimental cancer vaccine boosts effectiveness of existing treatment to 100% | Inquirer Technology

Experimental cancer vaccine boosts effectiveness of existing treatment to 100%

/ 05:37 PM September 11, 2018

INQUIRER.net Stock Photo

An experimental cancer vaccine has been found to boost the effectiveness of an existing treatment up to a 100 percent success rate.

The vaccine, developed by a team from UT Southwestern Medical Center, used a molecule called Diprovocim. It boosted the effectiveness of cancer-fighting cells in tandem with an existing cancer treatment, reports Drug Target Review.

Article continues after this advertisement

The study, co-led by Scripps Researcher Professor Dr. Dale Boger and Nobel laureate Bruce Beutler of Southwestern, was published in the Proceedings of the National Academy of Sciences of the United States of America.

FEATURED STORIES

The research team tested Diprovocim with anti-cancer therapy anti-PD-L1 and alum on mice with melanoma, an aggressive type of cancer that develops from pigment cells called melanocytes. Melanoma typically starts on the skin but may also develop in the mouth, eye or intestines. If treated early, melanoma can be cured, but it can be fatal if allowed to spread in the body.

Observations showed a 100 percent survival rate for the mice that received PD-L1 with Diprovocim. A 25 percent survival rate was observed with PD-L1 plus alum, and zero survival for those that only got PD-L1 treatment.

Article continues after this advertisement

What the vaccine did was to stimulate the immune system to create and direct cancer-fighting cells, or tumor-infiltrating leukocytes, to attack tumors. Since immunotherapy procedures like PD-L1 already boost a body’s natural defenses, the added Diprovocim essentially put the system into overdrive.

Article continues after this advertisement

The Diprovocim molecule was also easy to synthesize, according to the scientists, which further made its medical application more promising.

Article continues after this advertisement

As an added result to the 100 percent success rate, the researchers found that the surviving mice developed a resistance when they tried to re-establish the tumor. “It wouldn’t take. The animal is already vaccinated against it,” said Boger.

Moving forward, the team planned to do other tests and see how Diprovocim works with other cancer therapies, which may target different forms of cancer.  Alfred Bayle /ra

Article continues after this advertisement

RELATED STORIES:

Scientists discover tiny tunnels connecting brain to skull

‘Laziness’ may be a good survival strategy—study

Your subscription could not be saved. Please try again.
Your subscription has been successful.

Subscribe to our daily newsletter

By providing an email address. I agree to the Terms of Use and acknowledge that I have read the Privacy Policy.

Scientists reverse aging in human cells

TOPICS: cancer treatment, cancer vaccine, immunotherapy
TAGS: cancer treatment, cancer vaccine, immunotherapy

Your subscription could not be saved. Please try again.
Your subscription has been successful.

Subscribe to our newsletter!

By providing an email address. I agree to the Terms of Use and acknowledge that I have read the Privacy Policy.

© Copyright 1997-2024 INQUIRER.net | All Rights Reserved

This is an information message

We use cookies to enhance your experience. By continuing, you agree to our use of cookies. Learn more here.